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Background: Drug-eluting stents (DES) have demonstrated reduction of late loss and target lesion revascularization rates through an inhibitory 
effect on neointimal hyperplasia but increased risk of late or very late stent thrombosis due to incomplete neointimal coverage. Difference in 
neointimal coverage between Zotarolimus-eluting stent (ZES) and Everolimus-eluting stent (EES) is unclear. 
Methods: Patients who received an implantation of ZES (n=40) or EES (n=38) were included in this study. Follow-up angiographic and angioscopic 
examinations were performed at 372±65 days later in ZES group and at 364±29 days later in EES group. Yellow color grade (grade 0-3), neointima 
coverage grade (grade 0-2), and thrombus (presence or absence) at stented lesion were evaluated by angioscopy. 
Results: Yellow color grade was higher in EES than in ZES (0.4±0.78 vs. 1.26±0.92, p<0.0001). Stent coverage was better in ZES than in EES 
(1.98±0.16 vs. 1.18±0.51, p<0.0001). Prevalence of thrombus was not different between ZES and EES. ZES had higher prevalence of white good 
neointima coverage, which is common in bare metal stents, than EES (97.5% vs. 18.4% p<0.0001). Neointima coverage was generally homogenous 
in both stents. 
Conclusions: Although ZES had higher prevalence of white and better neointima coverage than EES, both stents commonly had low incidence of 
in-stent thrombus formation.
